Apomorphine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 1, 2026🚩 Report this page

Apomorphine

Active ingredient · 2 therapeutic classes

Sold as KYNMOBI

GB MHRA

Drug class: Drugs Used In Erectile Dysfunction
Availability: See label
Markets covered: 1
Products on record: 5

G04BEDrugs Used In Erectile Dysfunction N04BCDopamine Agonists

Overview

Apomorphine is an active pharmaceutical ingredient in the Drugs Used In Erectile Dysfunction group (G04BE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	5	May 1, 2026

GBUnited Kingdom· MHRA

5 products

Uses

GBOfficial regulatory label· revised September 12, 2025[1]

The treatment of motor fluctuations ('on-off' phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication.

How to take

Drug interactions

Known interactions involving Apomorphine. Select one for details. This list is informational and not a complete interaction checker.

Alosetron Amiodarone Amisulpride Anagrelide Arsenic Trioxide Bedaquiline Bepridil Cabozantinib Ceritinib Chloroquine Cisapride Citalopram Crizotinib Disopyramide Dofetilide Dolasetron Dronedarone Droperidol Efavirenz Escitalopram Fingolimod Gatifloxacin Granisetron Grepafloxacin Halofantrine Haloperidol Hydroxychloroquine Ibutilide Iloperidone Ivabradine Ivosidenib Lefamulin Lumefantrine Macimorelin Mesoridazine Methadone Mifepristone Moxifloxacin Nilotinib Ondansetron Osimertinib Ozanimod Palonosetron Panobinostat Papaverine Pasireotide Pimozide Procainamide Propoxyphene Quinidine Saquinavir Selpercatinib Siponimod Sotalol Sparfloxacin Thioridazine Toremifene Vandetanib Vemurafenib Ziprasidone Abarelix Abiraterone Acebutolol Acetazolamide Acrivastine Adenosine Albuterol Alfentanil Alfuzosin Aliskiren Alprazolam Alprostadil Amiloride Amitriptyline Amlodipine Amobarbital Amoxapine Amyl Nitrite Apalutamide Apraclonidine Arformoterol Aripiprazole Asenapine Astemizole Atenolol Atomoxetine Azatadine Azilsartan Azithromycin Baclofen Benazepril Bendroflumethiazide Benzhydrocodone Benzthiazide Betaxolol Bicalutamide Biperiden Bisacodyl Bisoprolol Bosutinib Brexanolone Brexpiprazole Brimonidine Brivaracetam Bromocriptine Brompheniramine Bumetanide Buprenorphine Bupropion Buspirone Butabarbital Butalbital Butorphanol Cabergoline Cannabidiol Captopril Carbamazepine Carbinoxamine Cariprazine Carisoprodol Carteolol Carvedilol Castor Oil Cenobamate Chlorcyclizine Chlordiazepoxide Chlormezanone Chlorothiazide Chlorphenesin Chlorpheniramine Chlorpromazine Chlorthalidone Chlorzoxazone Cilostazol Ciprofloxacin Clarithromycin Clemastine Clevidipine Clobazam Clofazimine Clomipramine Clonazepam Clonidine Clorazepate Clozapine Codeine Cyclandelate Cyclizine Cyclobenzaprine Cyproheptadine Dantrolene Dasatinib Daunorubicin Degarelix Deserpidine Desipramine Deutetrabenazine Dexbrompheniramine Dexmedetomidine Dextromethorphan Dezocine Diazepam Diazoxide Dichloralphenazone Dihydrocodeine Diltiazem Dimenhydrinate Diphenhydramine Donepezil Doxazosin Doxepin Doxorubicin Doxylamine Dronabinol Enalapril Encorafenib Entacapone Entrectinib Enzalutamide Epirubicin Eplerenone Epoprostenol Eprosartan Eribulin Erythromycin Esketamine Esmolol Estazolam Eszopiclone Ethacrynate Ethanol Ethchlorvynol Ethotoin Etomidate Ezogabine Famotidine Felbamate Felodipine Fenoldopam Fentanyl Flavoxate Flecainide Flibanserin Fluconazole Fluoxetine Fluphenazine Flurazepam Flutamide Formoterol Foscarnet Fosinopril Fosphenytoin Fostemsavir Furosemide Gabapentin Galantamine Gemifloxacin Gilteritinib Glasdegib Glycerin Goserelin Guanabenz Guanadrel Guanethidine Guanfacine Halazepam Halothane Histrelin Hydralazine Hydrochlorothiazide Hydrocodone Hydroflumethiazide Hydromorphone Hydroxyzine Idarubicin Ifosfamide Iloprost Imipramine Indacaterol Indapamide

Showing 240 of 480. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL044830074 · revised September 12, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Selection of Patients Suitable for APO-go injections:
Patients selected for treatment with APO-go should be able to recognise the onset of their ‘off’ symptoms and be capable of injecting themselves or else have a responsible carer able to inject for them when required. Patients treated with apomorphine will usually need to start domperidone at least two days prior to initiation of therapy.
The domperidone dose should be titrated to the lowest effective dose and discontinued as soon as possible. 4). Apomorphine should be initiated in the controlled environment of a specialist clinic. g. neurologist). The patient’s treatment with levodopa, with or without dopamine agonists, should be optimised before starting APO-go treatment.
Posology Continuous Infusion Patients who have shown a good ‘on’ period response during the initiation stage of apomorphine therapy, but whose overall control remains unsatisfactory using intermittent injections, or who require many and frequent injections (more than 10 per day), may be commenced on or transferred to continuous subcutaneous infusion by minipump and / or syringe driver as follows:- The choice, of which minipump and / or syringe-driver to use, and the dosage settings required, will be determined by the physician in accordance with the particular needs of the patient.
2 ml) per hour then increased according to the individual response each day. 5 mg at intervals of not less than 4 hours. 06 mg/kg/hour. Infusions should run for waking hours only. Unless the patient is experiencing severe night-time problems, 24 hour infusions are not advised.
Tolerance to the therapy does not seem to occur as long as there is an overnight period without treatment of at least 4 hours. In any event, the infusion site should be changed every 12 hours. Patients may need to supplement their continuous infusion with intermittent bolus boosts, as necessary, and as directed by their physician.
A reduction in dosage of other dopamine agonists may be considered during continuous infusion. Establishment of treatment. Alterations in dosage may be made according to the patient’s response. The optimal dosage of apomorphine hydrochloride varies between individuals but, once established, remains relatively constant for each patient.
Precautions on continuing treatment The daily dose of APO-go varies widely between patients, typically within the range of 3-30 mg. It is recommended that the total daily dose of apomorphine HCl should not exceed 100 mg. In clinical studies it has usually been possible to make some reduction in the dose of levodopa; this effect varies considerably between patients and needs to be carefully managed by an experienced physician.
Once treatment has been established domperidone therapy may be gradually reduced in some patients but successfully eliminated only in a few, without any vomiting or hypotension. 3). Elderly The elderly are well represented in the population of patients with Parkinson’s disease and constitute a high proportion of those studied in clinical trials of APO-go.
The management of elderly patients treated with APO-go has not differed from that of younger patients. However, extra caution is recommended during initiation of therapy in elderly patients because of the risk of postural hypotension.
4). Method of Administration APO-go PFS 5 mg/ml Solution for Infusion in Pre-filled Syringe is a pre-diluted pre-filled syringe intended for use without dilution as a continuous subcutaneous infusion by minipump and / or syringe-driver.
It is not intended to be used for intermittent injection. Apomorphine must not be used via the intravenous route. Do not use if the solution has turned green. The solution should be inspected visually prior to use. Only clear, colourless and particle free solution should be used.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised September 12, 2025[1]

Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data) Blood and lymphatic system disorders Uncommon: Haemolytic anaemia and thrombocytopenia have been reported in patients treated with apomorphine.
Rare:
Eosinophilia has rarely occurred during treatment with apomorphine HCl.
Immune system disorders Rare:
Due to the presence of sodium metabisulphite, allergic reactions (including anaphylaxis and bronchospasm) may occur.
Psychiatric disorders Very common:
Hallucinations Common: Neuropsychiatric disturbances (including transient mild confusion and visual hallucinations) have occurred during apomorphine HCl therapy. 4). Aggression, agitation.
Nervous system disorders Common:
Transient sedation with each dose of apomorphine HCl at the start of therapy may occur; this usually resolves over the first few weeks. Apomorphine is associated with somnolence. Dizziness / light-headedness have also been reported.
Uncommon:
Apomorphine may induce dyskinesias during ‘on’ periods, which can be severe in some cases, and in a few patients may result in cessation of therapy. Apomorphine has been associated with sudden sleep onset episodes. 4. 4).
Respiratory, thoracic and mediastinal disorders Common:
Yawning has been reported during apomorphine therapy.
Uncommon:
Breathing difficulties have been reported. 2).
Skin and subcutaneous tissue disorders Uncommon:
Local and generalised rashes have been reported.
General disorders and administration site conditions Very common:
Most patients experience injection site reactions, particularly with continuous use. These may include subcutaneous nodules, induration, erythema, tenderness and panniculitis. Various other local reactions (such as irritation, itching, bruising and pain) may also occur.
Uncommon:
Injection site necrosis and ulceration have been reported.
Not known:
Peripheral oedema has been reported.
Investigations Uncommon:
Positive Coombs' tests have been reported for patients receiving apomorphine. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

GBOfficial regulatory label· Warnings and precautions· revised September 12, 2025[1]

Apomorphine HCl should be given with caution to patients with renal, pulmonary or cardiovascular disease and persons prone to nausea and vomiting. Extra caution is recommended during initiation of therapy in elderly and/or debilitated patients.
Since apomorphine may produce hypotension, even when given with domperidone pretreatment, care should be exercised in patients with pre-existing cardiac disease or in patients taking vasoactive medicinal products such as antihypertensives, and especially in patients with pre-existing postural hypotension.
Since apomorphine, especially at high dose, may have the potential for QT prolongation, caution should be exercised when treating patients at risk for torsades de pointes arrhythmia. When used in combination with domperidone, risk factors in the individual patient should be carefully assessed.
This should be done before treatment initiation, and during treatment. Important risk factors include serious underlying heart conditions such as congestive cardiac failure, severe hepatic impairment or significant electrolyte disturbance.
Also medication possibly affecting electrolyte balance, CYP3A4 metabolism or QT interval should be assessed. Monitoring for an effect on the QTc interval is advisable. An ECG should be performed: − prior to treatment with domperidone − during the treatment initiation phase − as clinically indicated thereafter The patient should be instructed to report possible cardiac symptoms including palpitations, syncope, or near-syncope.
They should also report clinical changes that could lead to hypokalaemia, such as gastroenteritis or the initiation of diuretic therapy. At each medical visit, risk factors should be revisited. Apomorphine is associated with local subcutaneous effects.
These can sometimes be reduced by the rotation of injection sites or possibly by the use of ultrasound (if available) in order to avoid areas of nodularity and induration. Haemolytic anaemia and thrombocytopenia have been reported in patients treated with apomorphine.
Haematology tests should be undertaken at regular intervals as with levodopa, when given concomitantly with apomorphine. 5). Neuropsychiatric problems co-exist in many patients with advanced Parkinson’s disease. There is evidence that for some patients neuropsychiatric disturbances may be exacerbated by apomorphine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations